Research and Clinical Trials on Risperidone (Risperdal)

Risperidone (Risperdal) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Risperidone (Risperdal).

• Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
  Status: Recruiting, Condition Summary: Schizophrenia
• Effect of Add-on Citalopram to Risperidone on Negative Symptoms in Schizophrenia
  Status: Completed, Condition Summary: Schizophrenia; Negative Symptoms
• A Study of the Effectiveness and Safety of Long Acting Risperidone in Patients With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment
  Status: Completed, Condition Summary: Risperdal Consta; Schizophrenia; Schizoaffective Disorders
• Intramuscular Injections of Risperidone 4-Week Long-Acting Injectable (LAI) Formulation in the Buttock of Subjects With Schizophrenia
  Status: Active, not recruiting, Condition Summary: Schizophrenia; Risperidone, Psychotic Disorders
• High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
  Status: Recruiting, Condition Summary: Schizophrenia; Schizoaffective Disorder
• Comparison of the Subjective Well-Being and Tolerability of Quetiapine XR to Risperidone
  Status: Active, not recruiting, Condition Summary: Schizophrenic Disorders
• Evaluation of the Usefulness to Doctors of the Risperdal® Consta® Treatment Guidebook Over a Three-Month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-Acting Risperidone by Injection
  Status: Completed, Condition Summary: Psychotic Disorders; Schizophrenia
• Risperidone Long-Acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
  Status: Active, not recruiting, Condition Summary: Schizophrenia; Psychotic Disorders; Substance Abuse; Alcohol Abuse
• Risperdal Consta for Bipolar Disorder
  Status: Active, not recruiting, Condition Summary: Bipolar I Disorder
• A 4-Week Study of Mifepristone in the Prevention of Risperidone-Induced Weight Gain in Healthy Male Volunteers
  Status: Completed, Condition Summary: Healthy
• A Double-Blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa
  Status: Active, not recruiting, Condition Summary: Anorexia Nervosa
• Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions
  Status: Completed, Condition Summary: Healthy
• Risperidone 1 mg Tablets Dosed in Healthy Subjects Under Fed Conditions
  Status: Completed, Condition Summary: Healthy
• Risperidone LA Study
  Status: Recruiting, Condition Summary: Psychosis; Schizophrenia
• A Study of the Efficacy and Safety of Long-Acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia
  Status: Completed, Condition Summary: Schizophrenia

 

Get These Clinical Trials as a Newsfeed

Risperidone:             

Current Research Literature on Risperidone (Risperdal)

Here are abstracts for some of the latest research articles to have appeared on Risperidone (Risperdal):

Long-acting risperidone: a review of its role in the treatment of bipolar disorder.

Adv Ther. 2009 Jun 26;
Kemp DE, Canan F, Goldstein BI, McIntyre RS
Bipolar disorder is a multidimensional illness typified by fluctuating periods of depression and mania, cognitive dysfunction, abnormal circadian rhythms, and multiple comorbid psychiatric and general medical conditions. Indefinite pharmacological treatment is often required, yet the modest effects of available treatments and frequent difficulties with tolerability and adherence present complex challenges to patients. Long-acting injectable medications offer a therapeutic alternative to oral mood stabilizers and may help facilitate long-term treatment adherence. This article will provide a succinct review of the latest data on the use of long-acting injectable risperidone (LAR) during the maintenance-phase treatment of bipolar disorder. The specific role of LAR in comparison to other atypical antipsychotics, and the limitations of available studies will be discussed from the perspectives of efficacy, tolerability, and sequential positioning in treatment guidelines.

Combination therapy or monotherapy for the depressed type of schizoaffective disorder.

Neuropsychiatr Dis Treat. 2009; 5: 91-101
Izáková L, Andre I, Halaris A
Several studies have demonstrated the effectiveness of adjunctive antidepressant drug therapy to improve the depressive or negative symptoms of schizoaffective disorder, however, monotherapy with atypical antipsychotics may be advantageous. We compared the efficacy and safety of risperidone monotherapy versus combination therapy of haloperidol with sertaline for the acute treatment of schizoaffective disorder, depressed type. This is an open label study of 52 female inpatients randomly assigned to risperidone alone (N = 26) or haloperidol in combination with sertraline (N = 26) for 12 weeks. The mean daily doses of medications were: risperidone: 3.75-3.29 mg/day, haloperidol: 5.35-4.15 mg/day, sertraline: 65.39-133.82 mg/day. Efficacy was measured using clinical rating scales of treatment, safety, and tolerability. Risperidone patients showed statistically significant greater improvement than haloperidol-sertraline patients on efficacy measures including Positive and Negative Syndrome Scale and Clinical Global Impressions rating. A higher number of risperidone patients dropped out of the study early. Fewer adverse events and lesser need for concomitant medications occurred in patients on risperidone. The risperidone group showed better psychological, social and occupational functioning (Global Assessment of Functioning) and higher quality of life (Heinrich's Quality of Life Scale). Risperidone has higher antipsychotic efficacy and tolerability compared with haloperidol-sertraline combination for the acute treatment of schizoaffective disorder, depressed type. Both treatments were comparable in terms of antidepressant efficacy.

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone.

Neuropsychiatr Dis Treat. 2009; 5: 47-54
Liu-Seifert H, Kinon BJ, Tennant CJ, Sniadecki J, Volavka J
OBJECTIVE: To better understand sexual dysfunction in patients with schizophrenia and its associations with prolactin and reproductive hormones. METHODS: This was a secondary analysis of an open-label, one-day study (N = 402). The primary objective of the study was to assess the prevalence of hyperprolactinemia in patients with schizophrenia who had been treated with conventional antipsychotics or risperidone. Other atypical antipsychotics available at the time of the study were not included due to a more favorable prolactin profile. RESULTS: The majority of patients (59% of females and 60% of males) reported impairment of sexual function. In postmenopausal females, risk of impaired sexual interest was increased by 31% for every 10 ng/ml increase in prolactin (p = 0.035). In males, lower testosterone was associated with higher prolactin (p < 0.001) and with orgasmic (p = 0.004) and ejaculatory dysfunction (p = 0.028). CONCLUSION: These findings suggest that hyperprolactinemia may be associated with sexual dysfunction. They also provide more information on the relationships between prolactin, reproductive hormones, and sexual dysfunction. Sexual dysfunction is an understudied yet important consideration in the treatment of schizophrenia. More attention is warranted in this area as it may provide opportunities for improved quality of life and adherence to treatment for patients.

Long-term efficacy of electroconvulsive therapy combined with different antipsychotic drugs in previously resistant shizophrenia.

Psychiatr Danub. 2009 Jun; 21(2): 179-86
Ravanić DB, Pantović MM, Milovanović DR, Dukić-Dejanović S, Janjić V, Ignjatović DR, Jović SD, Jurisić V, Jevtović I
BACKGROUND: In treatment-resistant schizophrenia a combination of ECT with antipsychotics has been reported to have superior outcomes compared to other strategies, however the results were inconsistent. We investigated the long-term effects of the combination of unilateral, non-dominant hemisphere ECT with three antipsychotics. SUBJECTS AND METHODS: The clinical study was a naturalistic, prospective, open-labeled, active-controlled study in adult outpatients of both genders suffering from treatment-resistant schizophrenia with a follow up of 2 years. The patients received sulpiride (n=17, 100-400mg/day, PO), risperidone (n=26, 2-8mg/day, PO) or olanzapine (n=27, 5-10mg/day, PO). Unilateral ECT was applied in 1 unit (0.5A, 0.8 mS) in six single applications, once a week and further according to the clinical need, in fortnight steps. Clinical efficacy was established using the PANSS and CGI psychometric scales. RESULTS: According to the results, the most effective treatment mode was olanzapine plus ECT, then risperidone plus ECT, while sulpiride plus ECT had lower clinical efficacy. Olanzapine plus ECT was significantly superior in all scale scores vs sulpiride plus ECT, as well as risperidone plus ECT except for PANSS-P (t=1.85, p>0.05). During the study, 38 of 70 patients were withdrawn due to treatment failure (n=21), side effects (n=6) and non-compliance (n=11). CONCLUSION: The combination of novel antipsychotics and ECT can be used safely and effectively in treatment-resistant schizophrenia.

Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder.

Gen Hosp Psychiatry. 2009 Jul-Aug; 31(4): 376-8
Hung CF, Huang TY, Lin PY
Hypothermia and rhabdomyolysis are infrequent adverse effects of antipsychotic drugs. Here we report a case of an adolescent with schizophreniform disorder who developed both of them simultaneously after intramuscular injection of olanzapine. A 17-year-old male patient was hospitalized for treatment of psychotic symptoms, which persisted on risperidone 3 mg/day for 3 weeks. Then his antipsychotic drug was shifted to oral olanzapine 10 mg/day. The next day, he received intramuscular injection of olanzapine 5 mg and soon developed hypothermia, rhabdomyolysis, hypotension and bradycardia. These symptoms subsided gradually in the next 2 weeks after supportive treatment was given. Such adverse effects were not observed in the following 7 months. Possible pharmacological mechanisms were discussed. Physicians should be cautious about patients' clinical symptoms after giving olanzapine injection or rapid titration in dosage.